AMAG stock forecast
Our latest prediction for AMAG Pharmaceuticals, Inc.'s stock price was made on the Jan. 10, 2020 when the stock price was at 11.52$.
In the short term (2weeks), AMAG's stock price should underperform the market by -3.65%. During that period the price should oscillate between -7.92% and +9.16%.
In the medium term (3months), AMAG's stock price should underperform the market by -7.14%. During that period the price should oscillate between -26.99% and +19.52%.Get email alerts
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
At the moment the company generates 326M USD in revenues.
On its last earning announcement, the company reported a loss of -8.47$ per share.
The book value per share is 21.09$
Three months stock forecastJan. 10, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|